Vericel Q1 revenue up 4% to $36.1M; net loss widens to $7.1M; reaffirms FY2022 guidance

Vericel Corp

2022-Q1 EPS reported -$0.15 revenue$36,074,000

Total net revenue $36.1M (+4% YoY); MACI $26.0M, Epicel $9.9M, NexoBrid $0.2M.
Net loss $7.1M ($0.15/share) vs $3.3M loss a year ago; non-GAAP adj. EBITDA $3.2M.
Reaffirmed FY2022 guidance: revenue $178-189M, gross margin ~70%, adj. EBITDA margin ~21%.
MACI and Epicel biopsies growing double-digit; NexoBrid BLA resubmission on track for mid-2022.
Appointed Mike Gilligan as VP, MACI National Sales.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.